Author: Contributor

Posted on

Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Article - Media

H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.

According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

 

Posted on

Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Article - Media

H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)

Christine Brown

SmarterAnalyst, 1 May 2020

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.

According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:Video: Ekso Bionics Killed by Naked Short Sellers – Thank You, HCWainwright for Front-Running Their Death

Posted on

Article: Famed short-seller David Einhorn calls out Tesla’s billing practices again, erasing the stock’s post-earnings gain

Article - Media

Famed short-seller David Einhorn calls out Tesla’s billing practices again, erasing the stock’s post-earnings gain

Business Insider, 30 April 2020

David Einhorn of Greenlight Capital has again taken to Twitter to call out Tesla’s accounting practices in a message directed at CEO Elon Musk.

“Dear Elon, I guess the offer of a factory tour was never serious,” Einhorn, a long-time Tesla bear and short-seller, tweeted Thursday. “I remain curious about your accounts receivable.”

Shares of Tesla pared gains from earlier in the day and traded down as much as 3% following Einhorn’s comments.

Paywall Access to Full Article

Posted on

Article: Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20

Article - Media

Co-Diagnostics Inc. [CODX] stock Reiterated by H.C. Wainwright analyst, price target now $20

Brandon Evans

DBT News, 30 April 2020

Co-Diagnostics Inc. [NASDAQ: CODX] traded at a low on 04/29/20, posting a -8.57 loss after which it closed the day’ session at $12.37. The results of the trading session contributed to over 5099148 shares changing hands. Over the past one week, the price volatility of Co-Diagnostics Inc. stands at 10.98% while the volatility over the past one month is 12.61%.

The market cap for CODX stock reached $332.63 million, with 26.89 million shares outstanding and 20.80 million shares in the current float. Compared to the average trading volume of 12.82M shares, CODX reached a trading volume of 5099148 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:

Posted on

Article: H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

Article - Media

H.C. Wainwright Keeps Their Hold Rating on PDS Biotechnology (PDSB)

Ryan Adist

SmarterAnalyst, 30 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB) today. The company’s shares closed last Wednesday at $0.95, close to its 52-week low of $0.62.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

Posted on

Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Article - Media

Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Posted on

Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Article - Media

H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Posted on

Article: Inovio to expand manufacturing of COVID-19 vaccine candidate with new CEPI grant

Article - Media

Inovio to expand manufacturing of COVID-19 vaccine candidate with new CEPI grant

Ciara Linnane

MarketWatch, 30 April 2020

Inovio Pharmaceuticals Inc. INO, -14.30% said Thursday it has received another grant from the Coalition for Epidemic Preparedness Innovations, or CEPI, an Oslo-based organization, to help it expend manufacturing of its COVID-19 vaccine candidate.

Read full article.

Comment: This is how they force people to sell. Many people buy on margin and as it goes lower they need more money.

Posted on

Data: Energous Corporation (WATT)

Data

Energous Corporation (WATT)

Date Open High Low Close* Adj Close** Volume
Apr 30, 2020 2.1500 2.3400 2.0600 2.2400 2.2400 1,576,719
Apr 29, 2020 2.3800 2.4000 2.1200 2.1800 2.1800 2,100,600
Apr 28, 2020 2.2800 2.4500 2.2100 2.3200 2.3200 1,741,200
Apr 27, 2020 2.1000 2.4100 1.9100 2.3100 2.3100 3,809,200
Apr 24, 2020 2.3400 2.3500 2.1500 2.2600 2.2600 2,188,200
Apr 23, 2020 1.9900 2.4000 1.8000 2.3100 2.3100 6,828,600
Apr 22, 2020 2.6900 2.7400 2.0300 2.1800 2.1800 14,387,000
Apr 21, 2020 2.7300 4.1700 2.4500 2.6750 2.6750 123,722,000
Apr 20, 2020 1.0000 1.0700 0.9160 1.0450 1.0450 508,600

View data.

Comment: Do the math: Average sale was $3, now $2 = $50 million in profit in 6 trading days just by selling counterfeit shares.

Posted on

Article: H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Article - Media

H.C. Wainwright Maintains a Buy Rating on BerGenBio AS (BRRGF)

Christine Brown

SmarterAnalyst, 29 April 2020

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BerGenBio AS (BRRGF) today and set a price target of NOK66.00. The company’s shares closed last Monday at $1.23.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 8.2% and a 41.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

RELATED:
Posted on

Release: ALERT FROM FIRM THAT FILED THE LAWSUIT The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fifth Third Bancorp and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Release

ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fifth Third Bancorp and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

27 April 2020

Investors who purchased the Company’s securities between February 26, 2016 and March 6, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before June 8, 2020.

Read full release.

Posted on

Release: RM LAW Announces Class Action Lawsuit Against Bed Bath & Beyond Inc.

Release

RM LAW Announces Class Action Lawsuit Against Bed Bath & Beyond Inc.

27 April 2020

RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Bed Bath & Beyond, Inc. (“Bed Bath & Beyond” or the “Company”) (NASDAQ: BBBY) securities during the period from October 2, 2019 through February 11, 2020, inclusive (the “Class Period”).

Read full release.

Posted on

Release: DEADLINE ALERT BRAGAR EAGEL & SQUIRE, P.C. REMINDS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST AARON’S, INC. AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

Release

DEADLINE ALERT: BRAGAR EAGEL & SQUIRE, P.C. REMINDS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST AARON’S, INC. AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

26 April 2020

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Aaron’s, Inc. (NYSE: AAN) securities between March 2, 2018 and February 19, 2020 (the “Class Period”). Investors have until April 28, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Read full release.

Posted on

Release: DEADLINE ALERT Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Tupperware Brands Corporation and Encourages Investors to Contact the Firm

Release

DEADLINE ALERT Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Tupperware Brands Corporation and Encourages Investors to Contact the Firm

25 April 2020

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of investors that purchased Tupperware Brands Corporation (NYSE: TUP) securities between January 30, 2019 and February 24, 2020 (the “Class Period”). Investors have until April 27, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Read full release.

Posted on

Release: Rosen, A Globally Recognized Firm, Reminds Intelsat S.A. Investors of Important Deadline in Class Action – I

Release

Rosen, A Globally Recognized Firm, Reminds Intelsat S.A. Investors of Important Deadline in Class Action – I

24 April 2020

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intelsat S.A. (NYSE: I) between November 5, 2019 and November 18, 2019, inclusive (the “Class Period”) of the important June 8, 2020 deadline in the class action. The lawsuit seeks to recover damages for Intelsat investors under the federal securities laws.

Read full release.

THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?